Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Hits New 12-Month Low – Here’s What Happened

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) reached a new 52-week low during trading on Thursday . The company traded as low as $52.25 and last traded at $52.25, with a volume of 0 shares trading hands. The stock had previously closed at $52.25.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RCDTF shares. Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

The company has a market capitalization of $10.78 billion, a price-to-earnings ratio of 26.13 and a beta of 0.33. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.73. The firm’s 50 day simple moving average is $52.21 and its 200-day simple moving average is $52.02.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.